Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: relebactam

  • Imipenem, Cilastatin, Relebactam (Recarbrio)

    In July 2019, the Food and Drug Administration (FDA) approved imipenem, cilastatin, relebactam for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis and complicated intra-abdominal infections (cIAI).